LEADER 03523nam  22006015  450 
001 9910349443103321
005 20200630204152.0
010   $a3-030-31000-0
024 7 $a10.1007/978-3-030-31000-4
035   $a(CKB)4100000009374663
035   $a(DE-He213)978-3-030-31000-4
035   $a(MiAaPQ)EBC5904652
035   $a(PPN)248600966
035   $a(EXLCZ)994100000009374663
100   $a20190924d2019      u|         0
101 0 $aeng
135   $aurnn|008mamaa
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aAdvancing Gene Fusion Detection Towards Personalized Cancer Nanodiagnostics           /$fby Kevin M. Koo
205   $a1st ed. 2019.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2019.
215   $a1 online resource (XIII, 102 p.) 
225 1 $aSpringer Theses, Recognizing Outstanding Ph.D. Research,$x2190-5053
311   $a3-030-30999-1 
327   $aUnifying Next-Generation Biomarkers and Nanodiagnostic Platforms for Precision Prostate Cancer (PCa) Management -- Colorimetric Gene Fusion Diagnostics for Visual Binary Readout -- Label ?Free Surface-Enhanced Raman Scattering Detection System for Clinical Biomarker Targets -- Amplification-Free Electrochemical RNA Biomarker Sensing -- Simultaneous Analysis of Multiple Biomarkers via High-Throughput Parallel Profiling.
330   $aThis book presents a unique concept of merging nanotechnology and novel urinary biomarkers for accurate early prostate cancer detection, discussing an entire progressive pipeline of innovative new strategies in biosensor development, from a simple colorimetric system to a complex system for simultaneous multiple biomarker sensing. For newcomers to the field of nucleic acid biosensing, it also describes various isothermal amplification and amplification-free strategies, which are currently the main research areas. Lastly, the book introduces and demonstrates the notion of clinical nanobiosensor validation toward clinical translation: the ultimate aim of researchers in the biosensor field. This book is a valuable reference resource learners seeking inspiration for cancer biosensor development.
410  0$aSpringer Theses, Recognizing Outstanding Ph.D. Research,$x2190-5053
606   $aBiomedical engineering
606   $aNanotechnology
606   $aCancer research
606   $aBiomedical Engineering/Biotechnology$3https://scigraph.springernature.com/ontologies/product-market-codes/B24000
606   $aNanotechnology$3https://scigraph.springernature.com/ontologies/product-market-codes/Z14000
606   $aBiomedical Engineering and Bioengineering$3https://scigraph.springernature.com/ontologies/product-market-codes/T2700X
606   $aCancer Research$3https://scigraph.springernature.com/ontologies/product-market-codes/B11001
615  0$aBiomedical engineering.
615  0$aNanotechnology.
615  0$aCancer research.
615 14$aBiomedical Engineering/Biotechnology.
615 24$aNanotechnology.
615 24$aBiomedical Engineering and Bioengineering.
615 24$aCancer Research.
676   $a610.28
676   $a610.28
700   $aKoo$b Kevin M$4aut$4http://id.loc.gov/vocabulary/relators/aut$0893268
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910349443103321
996   $aAdvancing Gene Fusion Detection Towards Personalized Cancer Nanodiagnostics$91995456
997   $aUNINA